JACC This Week cover art

All Episodes

JACC This Week — 728 episodes

#
Title
1

Season 2 Wrap-Up: Thank You, Reflections, and What Comes Next | JACC This Week

2

March 31, 2026: Global Cardiovascular Insights & Breakthroughs from China | JACC This Week

3

March 24, 2026: Cardiometabolic Health, COVID Impact & Prevention Science | JACC This Week

4

March 17, 2026: Heart Failure, Chagas Research & AI in Cardiology | JACC This Week

5

March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this Week

6

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means | JACC This Week

7

February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC This Week

8

JACC This Week Bonus Episode – Women's Cardiovascular Health: From Inclusion to Redesign

9

February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Redesign | JACC This Week

10

February 10, 2026: Amyloidosis in Focus: Diagnosis Delays, Early Treatment, and What Clinicians Must Know | JACC This Week

11

February 3, 2026: A New Season of JACC This Week: Valve Disease, Editorial Vision, and Engaging the Global Cardiology Community | JACC This Week

12

December 2, 2025: Global CVD 1990–2023: Trends, Risks, and the Road Ahead | JACC This Week

13

November 25, 2025: Clonal Hematopoiesis, Alcohol and Blood Pressure, Long-Term Risk, and Emerging Biomarkers | JACC This Week

14

November 18, 2025: Adiposity, Heart Failure, and the Future of Cardiometabolic Care | JACC This Week

15

November 11, 2025: Precision, Place, and the Future of Cardiovascular Prediction | JACC This Week

16

November 4, 2025: The 2025 Hypertension Guideline: A New Era in Blood Pressure Control | JACC This Week

17

October 28.2025: How Low Should We Go? | JACC This Week

18

October 21, 2025 - The Adipokine Hypothesis, Adipose-Cardiac Signaling, Sex Differences, Therapeutic Implications, and Diverse Populations | JACC This Week

19

October 14, 2025 - Emerging Frontiers in Cardiovascular Medicine: From Certification Reform to Inflammation Targeting | JACC This Week

20

October 7, 2025: AI in Scientific Writing and New Frontiers in Cardiovascular Care | JACC This Week

21

Computable Quality, Community Screening, and TAVR Debate | JACC This Week

22

AI, Polygenic Risk Scores, and Antithrombotic Therapy | JACC This Week

23

Reframing Cardiovascular Care | JACC This Week

24

Heart Failure Insights, AI Standards, and Genetic Clues | JACC This Week

25

Cognitive Risk in CHD and Cardiology Practice Meets Lifestyle Realities | JACC This Week

26

Pacing Strategies, Air Quality, and the Path to Equity | JACC This Week

27

Device Safety, DAPT Strategy & Structural Innovation | JACC This Week

28

Amyloidosis in Focus: Biomarkers, Structural Insights & Therapeutic Strategy | JACC This Week

29

Out-of-Hospital Cardiac Arrest in Septuagenarians, Octogenarians, and Nonagenarians in Japan: Trends and Patterns in Outcomes | JACC Baran

30

Zeroing In on Prevention: ARIC and the Future of Cardiovascular Risk | JACC Baran

31

Epidemiology and Outcomes in HFimpEF | JACC Deep Dive

32

Heart Failure in Practice: Dual Therapy Insights, Digital Innovation & the Future of Risk Models | JACC This Week

33

JACC Editor's Page: June 30, 2025 | JACC

34

JACC Editor's Page: July 7. 2025 | JACC

35

IHCA Incidence Rates | JACC Deep Dive

36

Plaque Vulnerability and Risk Factors | JACC Deep Dive

37

Validation of AHA PREVENT in Healthcare Populations | JACC Deep Dive

38

ACURATE neo2 Under-Expansion | JACC Deep Dive

39

Structural Heart Disease, Obesity-Related Heart Failure, Private Equity Ownership in Hospitals | JACC This Week

40

Prevention in Focus: Polypill Projections, Risk Equations & Global Syndemic Trends | JACC This Week

41

Cardiovascular Interventions in Focus: Plaque Vulnerability, PCI Outcomes & Outpatient Cardiac Care Trends | JACC This Week

42

Electrophysiology in Focus: AFIB Management, LAA Closure Insights and Stroke Risk Strategies | JACC This Week

43

Podcasts at JACC: Past and Future | JACC This Week

44

JACC Editor's Page: June 23, 2025 | JACC

45

Wildfire-Linked Heart Failure, Impella Trial Insights, Cognitive Impairment in CVD & New Mortality Data | JACC This Week

46

JACC Editor's Page: June 16, 2025

47

June 24, 2025 Issue Summary | JACC

48

Characterization of Arterial Aneurysms in Loeys-Dietz Syndrome | JACC

49

Differences in Arterial Events in Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome | JACC

50

Relationship between exercise-induced cardiac troponin elevations and occult coronary atherosclerosis in middle-aged athletes | JACC

51

Long-term Survival and Patient Reported Outcomes after Staged Reconstructive Surgery for Hypoplastic Left Heart Syndrome | JACC

52

Sleep and Heart Failure: LV Function Findings from the ADVENT-HF Trial | JACC Baran

53

JACC Editor's Page: June 9, 2025

54

June 17, 2025 Issue Summary | JACC

55

10-Year and 30-Year Risks of Cardiovascular Disease in the U.S. Population | JACC

56

Predicting Heart Failure Outcomes Using Patient-Reported Health Status: Real-World Validation of the KCCQ-12 | JACC

57

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of an International Multicenter Prospective Registry | JACC

58

Long-acting Factor XI Inhibition and Peri-procedural Bleeding: An Analysis from AZALEA-TIMI 71 | JACC

59

ACS Guidelines | A Latin American Perspective | JACC

60

ACS Guidelines | Closer to a Universal Document | JACC

61

ACS Guidelines | Maturation of Lipid Management | JACC

62

ACS Guidelines | A Holistic View | JACC

63

ACS Guidelines | Gaps Within Evidence Gaps | JACC

64

ACS Guidelines | A Personal Perspective | JACC

65

ACS Guidelines | MCS in Acute Myocardial Infarction-Cardiogenic Shock | JACC

66

Chronic Stent Recoil: A Hidden Cost of Thinner Struts? | JACC Baran

67

June 10, 2025 Issue Summary | JACC

68

Acoramidis and Early sTTR Rise: Biomarker-Driven Insights into Survival | JACC Baran

69

June 3, 2025 Issue Summary | JACC

70

Insights From the INTERASPIRE Study | JACC Deep Dive

71

SORT OUT XI | EuroPCR.25 | JACC

72

VT Prevention in Repaired Tetralogy of Fallot: Mapping SCAI and Minimizing ICDs | JACC Baran

73

Vutrisiran Impact on Functional Capacity and QOL | JACC Deep Dive | JACC

74

May 27, 2025 Issue Summary | JACC

75

10 Year Outcome of DANAMI 3 PRIMULTI | JACC | EuroPCR.25 | JACC

76

Vutrisiran and Mortality in ATTR-CM | JACC | ESCHF25

77

Rethinking Rehab: ACTIVE-ADHF and the Power of Early Intervention | JACC Baran

78

Individual Variation in Tirzepatide Response | JACC Deep Dive

79

JACC Editor's Page: March 18, 2025 | JACC

80

May 20, 2025 Issue Summary | JACC

81

Altshock-2 Through a Regional Lens: IABP in HF-CS | JACC Baran

82

Disentangling the Impact of Adiposity From Insulin Resistance in HFpEF | JACC Deep Dive

83

Revisiting the SUMMIT Trial | JACC Deep Dive

84

JACC Editor's Page: May 13, 2025

85

Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results from ORBITA-2 | JACC

86

May 13, 2025 Issue Summary | JACC

87

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction and Obesity: the SUMMIT Trial | JACC

88

Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: the EMPEROR Program | JACC

89

Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure with Preserved Ejection Fraction | JACC

90

Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review | JACC

91

Aortic Stenosis Under Pressure: Decoding Low-Gradient Risk Profiles | JACC Baran

92

Sudden Cardiac Arrest in Young Athletes | JACC Deep Dive

93

1-Year Results of ADVANTAGE AF | JACC Deep Dive

94

May 6, 2025 Issue Summary | JACC

95

Advancing Electrophysiology: Innovations, Challenges, and the Future of Arrhythmia Management | JACC

96

Finerenone Reduces New-Onset Atrial Fibrillation across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis | JACC

97

Pulse Field Ablation for Persistent Atrial Fibrillation: One-Year Results of ADVANTAGE AF | JACC

98

Survival Outcomes after Sudden Cardiac Arrest in Young Competitive Athletes from the United States | JACC

99

Proactive mapping and preventive ablation reduce defibrillator implantation rates in Tetralogy of Fallot | JACC

100

State of the Art: Mapping Strategies to Guide Ablation in Ischemic Heart Disease | JACC

101

JACC Editor's Page: May 6, 2025 | JACC

102

Bridging Gaps for SCD Prevention in HCM: Why Regional Validation Matters | JACC Baran

103

Altshock-2 | JACC Deep Dive

104

April 29, 2025 Issue Summary | JACC

105

Advancing Care in Cardiogenic Shock: Evidence, Innovation, and Commitment | JACC

106

Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial | JACC

107

2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock | JACC

108

The Influence of Extracorporeal Life Support on Patients in Cardiogenic Shock Assessed by Machine Learning: A Machine Learning Subanalysis From the ECLS-SHOCK Trial | JACC

109

Single-Access Technique for Impella-Assisted Balloon Aortic Valvuloplasty and High-Risk PCI in Cardiogenic Shock | JACC

110

Nonhemorrhagic Pericardial Effusion With Tamponade and Cardiogenic Shock Due to Large Coronary Artery Fistula | JACC

111

LAVA-ECMO–Supported Dual-Transcatheter Aortic and Mitral Valve-in-Valve Replacement in Cardiogenic Shock | JACC

112

A Vascular Plug for Persistent Shock Following Transcatheter Mitral Valve Replacement | JACC

113

Mixed Cardiogenic-Vasodilatory Shock: Current Insights and Future Directions | JACC

114

JACC Editor's Page: April 29, 2025 | JACC

115

From Hokkaido to ACC: NT-proBNP Screening for Pre-Heart Failure in Rural Japan | JACC Baran

116

JACC Editor's Page: April 22, 2025 | JACC

117

April 22, 2025 Issue Summary | JACC

118

5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis | JACC

119

Pre-Pregnancy Adiposity, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk in Midlife | JACC

120

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry | JACC

121

Impact of Catheter Ablation of Atrial Fibrillation on Disease Progression | JACC

122

Conduction Disturbances After Transcatheter Aortic Valve Replacement: An Update on Epidemiology, Preventive Strategies, and Management | JACC

123

Troponin in Translation: The 0/1-Hour Algorithm Across Asia | JACC Baran

124

JACC Editor's Page: April 15, 2025 | JACC

125

April 15, 2025 Issue Summary | JACC

126

Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis | JACC

127

Genetic Risk and First-Trimester Cardiovascular Health Predict Hypertensive Disorders of Pregnancy in Nulliparous Individuals | JACC

128

Small Molecule PCSK9 Inhibitor for Hypercholesterolemia | JACC | ACC.25

129

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25

130

Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock | JACC | ACC.25

131

Individual Variation in Tirzepatide Response | JACC | ACC.25

132

Survival After Sudden Cardiac Arrest in Athletes | JACC | ACC.25

133

Self-Expanding Valve Outcomes at 5 Years Compared to Surgery | JACC | ACC.25

134

Gold Cards & Hidden Triggers: A New Look at Afib | JACC Baran

135

April 8, 2025 Issue Summary | JACC

136

New Threshold for Defining Mild Aortic Stenosis Derived from Velocity-Encoded MRI in 60,000 Individuals | JACC

137

Nonlinear Relation between Cardiac Mortality and Excess Temperature in Heatwaves: Exposure Response in 2.39 Million Patients | JACC

138

Impact of Transcather or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥Intermediate Risk | JACC

139

The Cardiovascular Care of the Pediatric Athlete | JACC

140

Incident Atrial Fibrillation in FINE-HEART | JACC | ACC.25

141

Use of Cardiac Rehab in Older Patients with MI Complicated by Cardiogenic Shock | JACC | ACC.25

142

Effect of plozasiran on lipoprotein particles by NMR | JACC | ACC.25

143

Exploring High-Gradient Aortic Stenosis | JACC Baran

144

Vutrisiran Efficacy by Baseline ATTR-CM Severity | JACC | ACC.25

145

April 1, 2025 Issue Summary | JACC

146

Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40-75 Years | JACC

147

Ensemble Deep Learning Algorithm for Structural Heart Disease Screening Using Electrocardiographic Images: PRESENT SHD | JACC

148

Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial | JACC

149

Invasive versus Conservative Management of Patients with Chronic Total Occlusion: Results From the ISCHEMIA Trial | JACC

150

Elevated remnant cholesterol contributes to the risk of peripheral artery disease: a Mendelian randomization study | JACC

151

Federal Funding Cuts & Aortic Valve Replacement Outcomes | JACC Baran

152

JACC Editor's Page: March 25, 2025 | JACC

153

March 25, 2025 Issue Summary | JACC

154

Worldwide Chronic Retrieval Experience of Helix-Fixation Leadless Cardiac Pacemakers | JACC

155

Can ICD Electrograms help Ventricular Tachycardia Ablation? Results From the Multicenter Randomized AIDEG-VTA Trial | JACC

156

Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | JACC

157

Antithrombotic Therapy to Minimize Total Events after ACS or PCI in Atrial Fibrillation: Insights from AUGUSTUS | JACC

158

Biomarker-based model for prediction of ischemic stroke in patients with atrial fibrillation | JACC

159

In CASTLE-HTx Trial We Trust | JACC

160

In the Wake of OCEANIC-AF is Factor XI inhibition Lost at Sea or Still Afloat? | JACC

161

Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-analysis of Randomized Trials | JACC

162

A New Era in Electrophysiology: Innovation, Integration, and Impact | JACC

163

Systolic BP & CV Mortality in US Adults Aged 80+ Taking Antihypertensive Medications| JACC | ACC.25

164

Managing Cardiogenic Shock Caused by Acute MI | JACC | ACC.25

165

Cognitive Function and Patient-Reported Outcomes after Cardiogenic Shock | JACC | ACC.25

166

RSV and Incidence of Cardiovascular Events | JACC | ACC.25 | JACC

167

Skype and Diaphragm Ultrasound in Heart Failure | JACC Baran

168

JACC Editor's Page: March 18, 2025 | JACC

169

March 18, 2025 Issue Summary | JACC

170

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure | JACC

171

Clinical Effect of Genetic Testing in Inherited Cardiovascular Diseases : A 14-Year Retrospective Study | JACC

172

Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy | JACC

173

Association between cigarette smoking and subclinical markers of cardiovascular harm | JACC

174

Best Practices for Imaging of Transcatheter Valve Failure: An Update from the Heart Valve Collaboratory | JACC

175

Clinical Considerations for Q1 Competitive Sports Participation for Athletes With Cardiovascular Abnormalities | JACC

176

Diagnostic Performance and Clinical Impact of Photon-Counting Detector CT in CAD | JACC Baran

177

March 11, 2025 Issue Summary | JACC

178

The Evolving Landscape of TAVR: A JACC Themed Issue | JACC

179

Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD | JACC

180

Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries | JACC

181

Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis | JACC

182

Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials | JACC

183

Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art Review | JACC

184

Advancing Transcatheter Aortic Valve Replacement: Expanding Evidence, Refining Strategies | JACC: Inside This Issue

185

P2Y12 Inhibitor Pretreatment in Non–ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry | JACC Baran

186

The Essential Role of Cardiovascular Surgery in Cardiology - JACC

187

The Essential Role of Cardiovascular Surgery in Cardiology: A Perspective From JACC | JACC

188

The Nonsyndromic Ascending Thoracic Aorta in a Population-Based Setting: A 5-Year Prospective Cohort Study | JACC

189

Days Alive Out of Health Care: A Novel Measure of Health Status After Congenital Heart Surgery | JACC

190

The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial | JACC

191

Long-Term Outcomes of Contemporary Surgical Repair for Degenerative Mitral Regurgitation | JACC

192

Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis | JACC

193

Domino Heart Valve Transplant in Children With Congenital Valve Disease: Short-Term Outcomes, Growth, and Immunosensitization | JACC

194

Introducing JACC-Baran & FINEARTS-HF Renal Function | JACC Baran

195

The Super Bowl & HCM Proteomics | JACC Baran

196

Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure: JACC Expert Panel From the HF-ARC

197

JACC - February 18, 2025 Issue Summary

198

Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial

199

Myocardial Fibroblast Activation After Acute Myocardial Infarction: A Positron Emission Tomography and Magnetic Resonance Study

200

Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is it DANGERous?

201

Associations of Short-Term Ozone Exposure With Hypoxia and Arterial Stiffness

202

Management of Coronary Stent Underexpansion

203

2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke: A Report of the American College of Cardiology Solution Set Oversight Committee

204

JACC - Preprints: A Revolution in Cardiovascular Science

205

Advancing Prevention: Insights From JACC's Focus Issue

206

Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study

207

Higher Aircraft Noise Exposure Is Linked to Worse Heart Structure and Function by Cardiovascular MRI

208

Accelerometer-Measured Sedentary Behavior and Risk of Future Cardiovascular Disease

209

Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study

210

Long-Term Lipid Lowering With Evolocumab in Older Individuals

211

Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States

212

Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry)

213

Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity

214

Incidental and Progressive Tobacco Smoking in Childhood and Subsequent Risk of Premature Cardiac Damage

215

Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial

216

Navigating the 2024 ESC Hypertension Guidelines: What Is New, Context, and Future Directions

217

JACC - Transforming Publishing: Your Paper, Your Way at JACC

218

JACC - February 4, 2025 Issue Summary

219

A Contemporary Picture of Coagulase-negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study

220

P2Y12 Inhibitor Pretreatment in Non-ST Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry

221

Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease

222

The Association of Hospital-Cardiologist Integration with Patient Outcomes, Care Quality, and Utilization

223

2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis

224

Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications: A State-of-the-Art Review

225

Tricuspid Valve Interventions: A New Era in Cardiovascular Innovation

226

Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial

227

Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results From a Large European Real-World Registry

228

Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort

229

Advanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy

230

Transcatheter Tricuspid Valve Replacement

231

The Amara Yad Project: A New Resource for Cardiac Anatomy

232

Amara Yad Image: The Tricuspid Valve

233

Transcatheter Interventions in Tricuspid Regurgitation: Shifting the Focus Beyond Quantity of Life to Quality of Life

234

Advances in Transcatheter Tricuspid Valve Interventions: Implications for Health Policy

235

A Comprehensive Exploration of FINEARTS-HF: A JACC Theme Issue

236

Use of Finerenone For Heart Failure And Intermediate Or Preserved Ejection Fraction: the Finearts-Hf Trial

237

Effect of Finerenone On the Kccq In Patients With Hfmref/Hfpef: a Prespecified Analysis of Finearts-Hf

238

Finerenone, Obesity, And Heart Failure With Mildly Reduced/Preserved Ejection Fraction: a Prespecified Analysis of Finearts-Hf

239

Finerenone And Kidney Outcomes In Patients With Heart Failure: the Finearts-Hf Trial

240

Initial Decline In Glomerular Filtration Rate With Finerenone In Hfmref/Hfpef: a Prespecified Analysis of Finearts-Hf

241

Did Finerenone Improve Health Status in the FINEARTS Trial?: A Critical Reevaluation of the Analysis of Patient-Reported Outcomes in Heart Failure

242

JACC - Obesity as a Disease | JACC

243

JACC - The Terminology of Obesity | JACC

244

JACC - Obesity Medication Usage | JACC

245

JACC - Obesity Medication Concerns | JACC

246

JACC - Shame and Blame | JACC

247

JACC - Is There Healthy Obesity? | JACC

248

JACC - The Cardiologist's Role in Treating Obesity | JACC

249

JACC - Should Cardiologists Care About Obesity? | JACC

250

JACC - January 7 - 14, 2025 Issue Summary

251

Drug-Coated Balloon Angioplasty Of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial

252

Optimal Strategy for Complete Revascularization in ST-Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis

253

Machine Learning-based Prediction of Death and Hospitalization in Patients with Implantable Cardioverter Defibrillators

254

Association of Systemic Thromboxane Generation with Risk of Developing Heart Failure

255

Effect of valve type and anesthesia strategy for TAVR – 5-year results of the SOLVE-TAVI trial

256

JACC - December 17 - 24, 2024 Issue Summary

257

Cardiac MRI Predictors of Arrhythmic Sudden Cardiac Events in Patients with Fontan Circulation

258

Oxidized Phospholipids and Calcific Aortic Valvular Disease

259

Impact of Renal & Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair

260

Excess Mortality and Hospitalizations Associated with Seasonal Influenza in Patients with Heart Failure

261

Anatomic and Physiologic Repair of Congenitally Corrected Transposition of the Great Arteries

262

JACC - December 10, 2024 Issue Summary

263

Major Bleeding and Mortality After Revascularization of Left Main Disease

264

Hospitalizations in Symptomatic Patients with Heart Failure and Moderate to Severe Functional Mitral Regurgitation: Insights from RESHAPE-HF2

265

Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Meta-analysis of Randomized Controlled Trials

266

Aspirin Monotherapy versus No Antiplatelet Therapy in Stable Patients with Coronary Stents Undergoing Low-to-Intermediate Risk Non-cardiac Surgery

267

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared with Placebo for Initial Treatment of Hypertension

268

JACC - December 3, 2024 Issue Summary

269

Two-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study

270

Hypertensive disorders of pregnancy increase risk for myocardial infarction: a population-based study

271

Artificial Intelligence-Enhanced Electrocardiogram Diastolic Function Assessment for Prognostic Stratification in Mitral Regurgitation

272

Length of Hospital Stay for Endocarditis. Before and After Partial Oral Treatment of Endocarditis Trial

273

Sudden Death in Obesity: Mechanisms and Management

274

Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of Four Trials

275

JACC - SUMMIT 2024: A Video Interview with Harlan Krumholz and Milton Packer| JACC | AHA 2024

276

JACC - Recap of AHA From Harlan Krumholz, Editor-in-Chief

277

JACC - Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure

278

JACC - Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity

279

JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

280

JACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024

281

JACC - Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial

282

JACC - Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study

283

JACC - DanGer Shock trial: The impact of age | JACC | AHA 2024

284

JACC - Oxidized Phospholipids and Calcific Aortic Valvular Disease

285

JACC - Accelerometer-Measured Sedentary Behavior & Risk of Future Cardiovascular Disease | JACC | AHA 2024

286

JACC - P2Y12 Inhibitor Pretreatment in Non-ST Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry

287

JACC - Hospital-Cardiologist Integration and Outcomes | JACC | AHA 2024

288

JACC - Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022

289

JACC - November 26, 2024 Issue Summary

290

Associations of Self-reported Race, Polygenic Risk, and Social Determinants of Health with Coronary Heart Disease

291

Prevalence and Impact of Recurrent Rejection on Pediatric Heart Transplant Recipients: A PHTS Multi-Institutional Analysis

292

ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction

293

Clinical implications of Pre-test probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension

294

Consequences of Discontinuation of Long-Term Treatment in Patients With Heart Failure and Reduced Ejection Fraction

295

JACC Journals at AHA | JACC | AHA 2024

296

JACC - November 19, 2024 Issue Summary

297

Screening for Undiagnosed Atrial Fibrillation and Stroke Prevention

298

Non-Modifiable Risk Factors Predict Outcomes in Brugada Syndrome

299

Intraoperative Conduction Mapping to Reduce Postoperative Atrioventricular Block in Complex Congenital Heart Disease

300

Embryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation

301

Ten Years of Leadless Cardiac Pacing

302

JACC - November 12, 2024 Issue Summary

303

Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Heart Failure: a EMPEROR Validation Cohort

304

Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy

305

Complete vs. Culprit-Only Revascularization in Older Patients with Myocardial Infarction with or without ST-segment elevation

306

Recaticimab Monotherapy for Non-Familial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial

307

Recaticimab as add-on therapy to statins for non-familial hypercholesterolaemia: the phase 3 REMAIN-2 trial

308

Artificial Intelligence in Cardiovascular Clinical Trials

309

Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs. Second-Generation DES: TARGET-IV NA Trial

310

Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial

311

Drug-Coated Balloon Angioplasty Of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial

312

Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD

313

JACC - November 5, 2024 Issue Summary

314

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

315

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy

316

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

317

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

318

Standard of Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

319

Family Screening in Hypertrophic Cardiomyopathy - Identification of Relatives with Low Yield from Systematic Follow-up

320

Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results From a Large European Real-World Registry

321

Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-year Outcomes From the TRILUMINATE Randomized Cohort

322

JACC - October 29, 2024 Issue Summary

323

Asymptomatic versus symptomatic hypotension with sacubitril/valsartan in heart failure and reduced ejection fraction in PARADIGM-HF

324

The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths.

325

FcγRIIa: A Marker of Cardiovascular Risk after Myocardial Infarction

326

AI-Facilitated Assessment of Built Environment Using Neighborhood Satellite Imagery and Cardiovascular Risk

327

Aspirin Hypersensitivity in Patients with Atherosclerotic Cardiovascular Disease

328

JACC - October 22, 2024 Issue Summary

329

Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure

330

Atrial fibrillation and semaglutide efficacy in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF Program

331

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease (FLOW Trial)

332

The Effect of Semaglutide on Mortality and COVID-19-Related Deaths - An Analysis From the SELECT Trial

333

Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program

334

JACC - The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial | EACTS 2024

335

JACC - October 15, 2024 Issue Summary

336

Minimum National Prevalence of Diagnosed Atrial Fibrillation inferred from California Acute Care Facilities

337

Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results

338

Heart failure risk assessment using biomarkers in patients with atrial fibrillation: Analysis from COMBINE-AF

339

Urinary Metal Levels and Coronary Artery Calcification: Longitudinal Evidence in the Multi-Ethnic Study of Atherosclerosis

340

International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence.

341

Part Two: Time to Significant Benefit of Finerenone in Patients With Heart Failure | JACC | HFSA 2024

342

Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial | JACC | HFSA 2024

343

JACC - October 8, 2024 Issue Summary

344

Prognostic Implications of Clinical- and Imaging Diagnostic Criteria for Myocarditis

345

Influence of subclinical atherosclerosis burden and progression on mortality

346

Arrhythmic Risk Stratification by Cardiovascular Magnetic Resonance Imaging in Patients with Non-ischemic Cardiomyopathy

347

Risk of Ischemic Stroke After Patent Foramen Ovale Closure

348

Contemporary Training in American Critical Care Cardiology: Minnesota Critical Care Cardiology Education Summit

349

ACC/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2024 Appropriate Use Criteria for Multimodality Imaging in Cardiovascular Evaluation of Patients Undergoing Nonemergent, Noncardiac Surgery

350

Time to Significant Benefit of Finerenone in Patients with Heart Failure | HFSA 2024

351

JACC - October 1, 2024 Issue Summary

352

Outcomes of Patients Undergoing Surgery for Complete Vascular Rings

353

Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients with Heart Failure and Hyperkalemia

354

Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults

355

Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol

356

Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients with Overt Chronic Kidney Disease: JACC State-of-the-Art Review

357

2024 ACC/AHA Key Data Elements and Definitions for Social Determinants of Health in Cardiology

358

Urinary Metal Levels and Coronary Artery Calcification: Longitudinal Evidence in the Multi-Ethnic Study of Atherosclerosis

359

JACC - September 24, 2024 Issue Summary

360

Short-term effects of lower air temperature and cold spells on myocardial infarction hospitalizations in Sweden

361

Recovery of Left Ventricular Function and Long-term Outcomes in Patients with Takotsubo Syndrome

362

Temporal Trends in Takotsubo Syndrome - Results from the International Takotsubo Registry

363

Predicting Long-term Clinical Outcomes of Patients with Recurrent Pericarditis

364

2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee

365

Interactions of Sleep Apnea with the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review

366

JACC - September 17, 2024 Issue Summary

367

Adverse Cardiovascular Outcomes in Patients with Obstructive Sleep Apnea and Obesity: Metabolic Surgery versus Usual Care

368

Effect of Evogliptin on the Progression of Aortic Valvular Calcification

369

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF

370

Prognostic value of plasma IgG N-glycome traits in pulmonary arterial hypertension

371

Genotype Guided Antiplatelet Therapy: JACC Review Topic of the Week

372

RESHAPE-HF2 Trial Findings | ESC 2024

373

Effect of Screening for Undiagnosed Atrial Fibrillation and on Stroke Prevention | ESC Congress

374

Insights from the SEQUOIA-HCM Trial and SEQUOIA-HCM CRM Substudy | ESC 2024

375

Insights from the SEQUOIA-HCM Trial and SEQUOIA-HCM CRM Substudy | ESC 2024

376

JACC - September 10, 2024 Issue Summary

377

Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood

378

Serial Shock Severity Assessment Within Seventy-Two Hours after Diagnosis: A Cardiogenic Shock Working Group Report

379

Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

380

Association of Postnatal Opioid Exposure and 2-year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery

381

Serial Shock Severity Assessment: Some Answers. Still Many Questions. | ESC 2024

382

Insights from RESHAPE-HF2 Trial | ESC 2024

383

A Secondary Analysis of DANFLU-1 Trial - High vs Standard Dose Influenza Vaccine in CKD | ESC 2024

384

Updates from the STEP-HFpEF Trial | ESC 2024

385

Updates from the SELECT Trial: Outcomes by Sex | ESC 2024

386

An Analysis From the SELECT Trial - COVID-19| ESC 2024

387

Insights from the FLOW Trial | ESC 2024

388

JACC - September 3, 2024 Issue Summary

389

Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-way Comparison from AUGUSTUS

390

Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Watchman FLX Left Atrial Appendage Occlusion

391

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM

392

Continuous Rhythm Monitoring with Implanted Loop Recorders in Children and Adolescents with Brugada Syndrome

393

Antithrombotic Strategies for Patients with Peripheral Artery Disease: JACC Scientific Statement

394

JACC - August 27, 2024 Issue Summary

395

Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials

396

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results

397

Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization

398

Deep Learning-Based Electrocardiogram Analysis Predicts Biventricular Dysfunction and Dilation in Congenital Heart Disease

399

Structural Cardiac Interventions in Patients with Heart Failure: JACC Scientific Statement

400

Treatment of Transcatheter Aortic Valve Thrombosis: JACC Review Topic of the Week

401

JACC - August 20, 2024 Issue Summary

402

Prescription Patterns for Sodium Glucose Cotransporter-2 Inhibitors in US Health Systems

403

Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes

404

Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR: Results of a Patient-Level Pooled Analysis

405

Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay

406

Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions

407

JACC - August 13, 2024 Issue Summary

408

Real-world 1-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study

409

Contemporary Pediatric Heart Transplant Waitlist Mortality

410

Comparison of Pressure vs Volume Overload Ventricular Wall Stress in Patients with Valvular Heart Disease

411

Myocardial Strain Measured by Magnetic Resonance Imaging Predicts Cardiovascular Morbidity and Death

412

Ending trans fat-the first-ever global elimination program for a noncommunicable disease risk factor: JACC International

413

JACC - August 6, 2024 Issue Summary

414

Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood

415

The influence of epicardial resistance on microvascular resistance reserve

416

A Patch Wearable Cardioverter Defibrillator for Patients at Risk of Sudden Cardiac Arrest

417

Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients with Type 2 Diabetes

418

Pericardial Diseases and Best Practices for Pericardiectomy: JACC State-of-the-Art Review

419

JACC - July 30, 2024 Issue Summary

420

Association of Adverse Clinical Outcomes with Peri-Infarct Ischemia Detected by Stress Cardiac Magnetic Imaging

421

Lipidomic Risk Score to Enhance Cardiovascular Risk Stratification for Primary Prevention

422

Temperature and Neurologic Outcomes in Neonates Undergoing Cardiac Surgery: A Society of Thoracic Surgeons Study

423

Mortality after Procedural or Spontaneous Myocardial Infarction

424

Treating Depression to Improve Survival in Coronary Heart Disease: What Have We Learned?

425

JACC - July 23, 2024 Issue Summary

426

Effects of Rapid Up-Titration of Neurohormonal Blockade in Patients with Acute Decompensated Heart Failure

427

Impact of Anatomical and Viability-guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy

428

Apixaban versus Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights from ARTESiA

429

OCT-Guided vs Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy

430

Sutureless Valves, a "Wireless" Option for Patients with Aortic Valve Disease: JACC State-of-the-Art Review

431

JACC - July 16, 2024 Issue Summary

432

Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial

433

Semaglutide and NYHA Class in Obesity-Related Heart Failure with Preserved Ejection Fraction: the STEP-HFpEF Program

434

Glycemic Control and Coronary Stent Failure in Patients with Type 2 Diabetes Mellitus

435

Percutaneous coronary revascularization strategies after myocardial infarction: a systematic review and network meta-analysis

436

The Role of Psychosocial Stress on Cardiovascular disease in Women: JACC-State-of-the-Art-Review

437

JACC - July 9, 2024 Issue Summary

438

Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients with Diabetic Cardiomyopathy

439

Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs

440

Impact of Lp(a) Level on LDL-Cholesterol or Apolipoprotein B-Related Risk of Coronary Heart Disease

441

Coronary artery bypass graft failure in women: incidence and clinical implications

442

Tricuspid Regurgitation in Patients with Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review

443

JACC - July 2, 2024 Issue Summary

444

Symptoms as a predictor of the placebo-controlled efficacy of PCI in stable coronary artery disease

445

N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention

446

Semaglutide and NTproBNP in Obesity-Related HFpEF: Insights from STEP-HFpEF Program

447

Prognostic Value of a 6-Minute Walk Test in Patients with Cardiac Transthyretin Amyloidosis

448

Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden

449

Lessons for Cardiovascular Clinical Investigators: the Tumultuous 2500-Year Journey of Physicians Who Ignited Our Fire

450

Transforming Cardiovascular Care with Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review

451

JACC - June 25, 2024 Issue Summary

452

Ten-Year Mortality after ST-Segment Elevation Myocardial Infarction Compared to the General Population

453

Timing of P2Y12-inhibitor Administration in Patients with STEMI Undergoing Primary PCI

454

Association of Autoimmune Diseases with Coronary Atherosclerosis Severity and Ischemic Events

455

Randomized Trial of a Vascular Care Team vs Education for Patients with Peripheral Artery Disease

456

Intravenous Iron Repletion for Patients with Heart Failure and Iron Deficiency: JACC State-of-the-Art Review

457

Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review

458

JACC - June 18, 2024 Issue Summary

459

SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy

460

Mineralocorticoid Receptor Antagonists in Patients with Heart Failure and Impaired Renal Function

461

Impact of Social Determinants of Health on Predictive Models for Outcomes after Congenital Heart Surgery

462

Geographical Mapping of Gender Disparities in Authorship of Cardiovascular Literature

463

2024 ACC/AHA/AACVPR/APMA/ ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

464

Artificial Intelligence for Cardiovascular Care — Part 1: Advances : JACC Review Topic of the Week

465

Artificial Intelligence in Cardiovascular Care — Part 2: Applications: JACC Review Topic of the Week

466

JACC - June 11, 2024 Issue Summary

467

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

468

Randomized Trial of Remote Assessment of Patients after an Acute Coronary Syndrome

469

Excess Apolipoprotein B and Cardiovascular Risk in Women and Men

470

Global, and Regional Cardiovascular Mortality Attributable to Non-optimal Temperatures over Time

471

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

472

Pollution and Cardiovascular Disease, Part 2: Water, Soil, Noise and Light Pollution: JACC Focus Seminar

473

Pollution and Cardiovascular Disease, Part 1: Environmentally Not So Friendly:Global Warming, Air Pollution,and Wildfires: JACC Focus Seminar

474

JACC - June 4, 2024 Issue Summary

475

Coronary Atherosclerotic Plaque Activity and Myocardial Infarction: A vessel-level analysis of the PRE18FFIR study

476

Effects of Sacubitril/Valsartan in Patients with Heart Failure Across the Spectrum of Kidney Risk

477

Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI

478

Transcatheter Covered Stent Exclusion of Superior Sinus Venosus Defects

479

Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review

480

Reperfusion Injury in Patients with Acute Myocardial Infarction: JACC: Scientific Statement

481

JACC - May 28, 2024 Issue Summary

482

Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Nonobstructive Hypertrophic Cardiomyopathy: Phase 2 Study

483

Clinical Outcome of Different Microvascular Injury Patterns after STEMI - A Multicenter Cardiac MRI Study

484

Prognostic Value of MRR After Primary PCI: a Pooled Analysis of Individual Patient Data

485

A Technology-Assisted Web Application for Consumer Access to a Non-prescription Statin Medication

486

Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review

487

Clinical Risk Assessment Across the Lifespan in Patients with Congenital Heart Disease: JACC Scientific Statement

488

JACC - May 21, 2024 Issue Summary

489

An Inclisiran First Strategy vs Usual Care in Patients with Atherosclerotic Cardiovascular Disease

490

Small Left Ventricle is Associated with an Increased Cardiovascular Risk in Patients with Atrial Fibrillation

491

Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial

492

Case Volumes and Outcomes among Early Career Interventional Cardiologists in the United States

493

Managing Implanted Cardiac Electronic Devices in Patients with Severe Tricuspid Regurgitation: JACC State-of-the-Art Review

494

Targeting the Substrate for Atrial Fibrillation: JACC Review Topic of the Week

495

JACC - May 14, 2024 Issue Summary

496

Prevalence of Cardiovascular Disease and Risk Factors among National Football League Alumni and Family Members

497

Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Cardiomyopathies

498

Uniform or Sex-Specific Cardiac Troponin Thresholds to Rule Out Myocardial Infarction at Presentation

499

Long-term Cardiovascular Risk Associated with Treatment of Attention-Deficit/Hyperactivity Disorder in Adults

500

Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5

501

JACC - May 7, 2024 Issue Summary

502

Combined effects of clonal hematopoiesis and degree of carotid stenosis on cardiovascular mortality

503

Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction

504

Association of Lipoprotein(a) Levels with Myocardial Infarction in Patients with Low Attenuation Plaque

505

Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients with Obstructive Sleep Apnea

506

JACC Focus Seminar on Mechanical Complications of Acute Myocardial Infarction

507

JACC - April 30, 2024 Issue Summary

508

Limb Outcomes with Ticagrelor Plus Aspirin in Patients with Diabetes Mellitus and Atherosclerosis

509

Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

510

Permanent Pacemaker Implantation and Long-term Outcomes of Patients Undergoing Concomitant Mitral and Tricuspid Valve Surgery

511

Association of Disrupted Delta Wave Activity During Sleep with Long-Term Cardiovascular Disease and Mortality

512

Malignant Hypertension – A Systemic Cardiovascular Disease: JACC Review Topic of the Week

513

JACC - April 16, 2024 Issue Summary

514

Variation in Health Status with Invasive vs Conservative Management of Chronic Coronary Disease

515

Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score

516

Water Conservation Overrides Osmotic Diuresis during SGLT2 Inhibition in Patients with Heart Failure

517

Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults with Congenital Heart Disease

518

2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction

519

The Clinical Challenge of Prosthetic Valve Endocarditis: JACC Focus Seminar

520

JACC - April 9, 2024 Issue Summary

521

Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction

522

Stratifying Disease Progression in Patients with Cardiac ATTR Amyloidosis

523

Efficacy and Safety of Dapagliflozin in Patients with Acute Heart Failure

524

Early Outcomes from a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry

525

Today's Infective Endocarditis: Not What You Learned in Medical School

526

JACC - April 2, 2024 Issue Summary

527

Validation of the ACC Expert Consensus Decision Pathway for Patients with Chest Pain

528

Risk of Dementia During Antihypertensive Drug Therapy in the Elderly

529

Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease

530

Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients with Cyanotic Congenital Heart Disease

531

JACC - March 26, 2024 Issue Summary

532

Prevalence and Outcomes of Patients With Discordant High-Gradient Aortic Stenosis

533

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure

534

Coarctation of Aorta With Tricuspid Aortic Valve Is Not Associated With Ascending Aortic Aneurysm

535

Frailty and Cognitive Function in Middle-Aged and Older Adults With Congenital Heart Disease

536

Genetic Factors Altering Immune Responses in Atrial Fibrillation: JACC Review Topic of the Week

537

JACC - March 19, 2024 Issue Summary

538

Association of Antiarrhythmic Drug Therapy with Syncope and Pacemaker Implantation in Patients with Atrial Fibrillation

539

Electrophysiological Characterization of Subclinical and Overt Hypertrophic Cardiomyopathy by Magnetic Resonance Imaging-Guided Electrocardiography

540

Kidney Injury After Minimal Radiographic Contrast Administration in Patients with Acute Coronary Syndromes

541

Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease

542

Histological Typing in Patients with Cardiac Amyloidosis: JACC Review Topic of the Week

543

JACC - March 12, 2024 Issue Summary: Dr. Valentin Fuster's Top Picks for 2023

544

JACC - March 5, 2024 Issue Summary

545

Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease

546

Surveillance Stress Testing After Percutaneous Intervention for Patients With Multivessel or Left Main Coronary Disease

547

Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI

548

Intraoperative Anemia Mediates Sex Disparity in Operative Mortality After Coronary Artery Bypass Grafting

549

Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review

550

JACC - February 27, 2024 Issue Summary

551

" Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular Mortality"

552

Phenotypic Expression and Clinical Outcomes in Patients with Arrhythmogenic Cardiomyopathies

553

Infective Endocarditis in Patients Addicted to Injected Opioid Drugs

554

Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer

555

"Food Is Medicine" Strategies for Nutrition Security and Cardiometabolic Health Equity: JACC State-of-the-Art Review

556

JACC - February 20, 2024 Issue Summary

557

Effect of a Salt Substitute on Incidence of Hypertension and Hypotension Among Normotensive Adults

558

Intrahepatic Transcriptomics Differentiate Advanced Fibrosis And Clinical Outcomes In Adults With Fontan Circulation

559

Increased Risk of Myocardial Infarction, Heart Failure And Atrial Fibrillation After Spinal Cord Injury

560

Vascular Regenerative Cell Deficiencies In South Asian Adults

561

Participation In Competitive Sports By Patients With Congenital Heart Disease: Aha/Acc And Eapc/Esc/Aepc Guidelines Comparison

562

JACC - February 13, 2024 Issue Summary

563

Randomized Trial of Effect of Bariatric Surgery On Blood Pressure After Five Years

564

Long-Term Efficacy of Evolocumab In Patients With Or Without Multivessel Coronary Disease

565

Bleeding Outcomes In Patients Treated With Asundexian In Phase Ii Trials

566

Implantable Hemodynamic Monitors Improve Survival In Patients With Heart Failure And Reduced Ejection Fraction

567

Measuring Coronary Blood Flow And Microvascular Resistance By Thermodilution: JACC Review Topic of the Week

568

JACC - February 6, 2024 Issue Summary

569

Outcomes According To Coronary Revascularization Modality In the Ischemia Trial

570

Universal Risk Prediction For Individuals With And Without Atherosclerotic Cardiovascular Disease

571

Large-Scale Proteomics Identifies Novel Biomarkers And Circulating Risk Factors For Aortic Stenosis

572

Clinical Presentation, Classification, And Outcomes of Cardiogenic Shock In Children

573

JACC - January 30, 2024 Issue Summary

574

Randomized Trial of Macitentan/Tadalafil Combination Therapy For Pulmonary Artery Hypertension

575

Transcatheter Edge-To-Edge Repair In Coapt-Ineligible Patients With Functional Mitral Regurgitation

576

Prognostic Implications of Initial Focal Contrast Enhancement In Acute Type B Intramural Hematoma

577

Growth of the Neo-Aortic Root And Prognosis of Transposition of the Great Arteries

578

Racial And Ethnic Disparities In Perioperative Health Care Among Patients Undergoing Cardiac Surgery: JACC State-of-the-Art Review

579

JACC - January 23, 2024 Issue Summary

580

Lipoprotein(A) is Markedly More Atherogenic Than Ldl: An Apolipoprotein B-Based Genetic Analysis

581

Guiding Intervention For Complex Coronary Lesions By Optical Coherence Tomography Or Intravascular Ultrasound

582

Risk of Death In Patients With Coronary Artery Disease Taking Nitrates And Phosphodiesterase-5-Inhibitors

583

Anxiety And Depression Symptoms In An International Study of Adults With Congenital Heart Disease

584

When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

585

JACC - January 16, 2024 Issue Summary

586

Rethinking False Positive Exercise Electrocardiographic Stress Tests By Assessing Coronary Microvascular Function

587

Sex-Specific Prognosis of Left Ventricular Size And Function Following Repair of Degenerative Mitral Regurgitation

588

Cardiac Reoperation Or Transcatheter Mitral Valve Replacement For Patients With Failed Mitral Prostheses

589

Comparison of Direct Oral Anticoagulants Vs Vitamin-K Antagonists After Transcatheter Mitral Valve Replacement

590

Sudden Cardiac Death In Young Athletes: Jacc State-Of-The-Art Review

591

JACC - January 2 - 9, 2024 Issue Summary

592

Health Status After Transcatheter Tricuspid-Valve Repair In Patients With Severe Tricuspid Regurgitation: Triluminate Pivotal Trial

593

Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After Pci: Stopdapt-2 5-Year Results

594

Contemporary Management And Outcomes of Patients With High-Risk Pulmonary Embolism

595

Lung-To-Heart Nano-In-Micro Peptide Promotes Cardiac Recovery In a Pig Model of Chronic Heart Failure

596

Antithrombotic Therapy For Patients Undergoing Cardiac Electrophysiological And Interventional Procedures: Jacc State-Of-The-Art Review

597

2023 Acc/Aha/Accp/Hrs Guideline For the Diagnosis And Management of Atrial Fibrillation

598

JACC - December 19 - 26, 2023 Issue Summary: A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action

599

JACC - December 12, 2023 Issue Summary

600

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in Seven Clinical Trials

601

Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events

602

Association of Lipoprotein(a) Levels with Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis

603

Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease

604

Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement

605

JACC - December 5, 2023 Issue Summary

606

Longitudinal Changes in Pulmonary Pressure in Late Life: The Atherosclerosis Risk in Communities (ARIC) Study

607

Systemic Atrioventricular Valve Surgery in Patients with Congenitally Corrected Transposition of the Great Vessels

608

Adjusting for Congenital Heart Surgery Risk Using Administrative Data

609

Neuroimaging and neurodevelopmental outcomes among individuals with complex congenital heart disease

610

Comparison of Intravascular Imaging, Functional or Angiographically Guided Coronary Intervention

611

JACC - November 28, 2023 Issue Summary

612

Determinants of Progression And Regression of Subclinical Atherosclerosis Over Six Years

613

Primary Prevention of Subclinical Atherosclerosis In Young Adults: Jacc Review Topic of the Week

614

Semaglutide Effects According to Ejection Fraction in Heart Failure with Preserved Ejection Fraction and Obesity

615

The Mortality Burden of Untreated Aortic Stenosis

616

Can Machine Learning Aid the Selection of Percutaneous vs. Surgical Revascularisation?

617

Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement

618

JACC - November 21, 2023 Issue Summary

619

Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation

620

Sleep-Related Hypoxia, Right Ventricular Dysfunction and Survival in Group 1 Pulmonary Arterial Hypertension: PVDOMICS Study

621

Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry

622

Long-Term Outcomes of Invasive vs Conservative Strategies for Older Patients with Non-ST-Elevation Acute Coronary Syndromes

623

Management of Adults with Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review

624

JACC - November 14, 2023 Issue Summary

625

Association of Age and Sex with Use of Transcatheter Aortic Valve Replacement in France

626

Multi-omics analysis provides novel pathways related to progression of heart failure

627

Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease

628

Deep Learning-Enabled Assessment of Left Heart Structure and Function Predicts Cardiovascular Outcomes

629

JACC - November 7, 2023 Issue Summary

630

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

631

Stress Perfusion Cardiac Magnetic Resonance vs SPECT Imaging for Detection of Coronary Artery Disease

632

Efficacy of Sotagliflozin in Adults with Type 2 Diabetes In Relation to Baseline Hemoglobin A1c

633

Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function

634

Implementation of Global Hearts Hypertension Control Programs in 32 Low- and Middle-Income Countries: JACC International

635

JACC - October 31, 2023 Issue Summary

636

Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy

637

Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives

638

Network Meta-analysis of Initial Antithrombotic Regimens after Left Atrial Appendage Occlusion

639

Public Out-of-hospital Cardiac Arrests in Residential Neighborhoods

640

Cardiovascular Fellowship Training in Cardio-Obstetrics: JACC Review Topic of the Week

641

JACC - October 24, 2023 Issue Summary

642

Psychosocial Characteristics of Women Presenting with Myocardial Infarction With or Without Obstructive Coronary Arteries

643

Impact of Positron Emission Tomographic Myocardial Perfusion Imaging on Patient Selection for Revascularization

644

Coronary Fractional Flow Reserve Assessment by Computerized Tomography in Patients with Type 2 Myocardial Infarction

645

Risk-Stratification for Hospital Mortality and Postoperative Complications in Patients with Shock undergoing Cardiac Surgery

646

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints

647

JACC - October 17, 2023 Issue Summary

648

Comparison of Antiplatelet Monotherapies after Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks

649

10-year Cardiovascular Risk in Patients with Newly-Diagnosed Type 2 Diabetes Mellitus

650

Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients with Suspected Coronary Artery Disease

651

Magnetic Resonance Spectroscopy of Brain Metabolism in Fetuses with Congenital Heart Disease

652

International Consensus on Differential Diagnosis and Management of Patients with Danon Disease: JACC State-of-the-Art Review

653

JACC - October 10, 2023 Issue Summary

654

Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events

655

Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice

656

Outcomes of Heart Transplant Donation after Circulatory Death

657

Prognostic Implications of the Extent of Cardiac Damage in Patients with Fabry Disease

658

Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review

659

Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the Week

660

JACC - October 3, 2023 Issue Summary

661

LDL-C reduction with lipid-lowering therapy for primary prevention of major vascular events among older individuals

662

Validation of Risk-Stratification for Cardiac Events in Pregnant Women with Valvular Heart Disease

663

Genetic Insights on the Relation of Vascular Risk Factors and Cervical Artery Dissection

664

Outcomes after Hybrid Palliation for Infants with Critical Left Heart Obstruction

665

Durable Mechanical Circulatory Support: JACC Scientific Statement

666

JACC - September 26, 2023 Issue Summary

667

Transcatheter Edge-to-Edge Repair in 5,000 Patients with Secondary Mitral Regurgitation: COAPT Post-Approval Study

668

Association of High-Sensitivity Cardiac Troponin-T with 30-day and Five-year Mortality after Cardiac Surgery

669

Impaired Renal Function and Major Cardiovascular Events in Young Adults

670

Chronic Medication Burden after Cardiac Surgery for Pediatric Medicaid Beneficiaries

671

Clinical Pathway for Coronary Atherosclerosis in Patients without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

672

JACC - September 19, 2023 Issue Summary

673

Impact of Complete Revascularization in the ISCHEMIA Trial

674

Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging with Cardiovascular Outcomes

675

20-Year Experience with Repair of Pulmonary Atresia or Stenosis and Major Aortopulmonary Collateral Arteries

676

Survival after Cardiac Transplantation in Adults with Single-Ventricle Congenital Heart Disease

677

Comprehensive Management of ANOCA Part 1 – Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review

678

Comprehensive Management of Anoca, Part 2—Program Development, Treatment, And Research Initiatives: Jacc State-Of-The-Art Review

679

JACC - September 12, 2023 Issue Summary

680

Long-term Outcome and Prognosis of Non-Infectious Thoracic Aortitis

681

Cardiovascular Events after Aortic Root Repair in Patients with Marfan Syndrome

682

Underutilization of Mineralocorticoid Antagonists in Patients with Heart Failure and Reduced Ejection Fraction

683

Vasovagal Responses to Human Monomorphic Ventricular Tachycardia: Hemodynamic Implications From Sinus Rate Analysis

684

Ventricular Arrhythmias in Adults with Congenital Heart Disease Part I: JACC State-of-the-Art Review

685

JACC - September 5, 2023 Issue Summary

686

Temporal trends in non-cardiovascular morbidity and mortality following acute myocardial infarction: A nationwide Danish study

687

Long-term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction

688

Trends in Mortality Following ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: 2003-2018

689

Efficacy of Dapagliflozin According To Geographical Location of Patients With Heart Failure

690

Ablation To Reduce Atrial Fibrillation Burden And Improve Outcomes: Jacc Review Topic of the Week

691

JACC - August 29, 2023 Issue Summary

692

Prevalence, Characteristics and Prognostic Relevance of Donor-Transmitted Coronary Artery Disease in Heart Transplant Recipients

693

Predictors of Mortality with a Fully Magnetically Levitated LVAD at 5-years: A MOMENTUM-3 Trial Analysis

694

Age-Tailored Monitoring of Myocardial Involvement in Arrhythmogenic Cardiomyopathy

695

Neighborhood Childhood Opportunity, Race/Ethnicity, and Surgical Outcomes in Children with Congenital Heart Disease

696

JACC - August 22, 2023 Issue Summary

697

Return-to-Play for Elite Athletes with Genetic Heart Diseases Predisposing to Sudden Cardiac Death

698

Cardiac Effects of Long Duration Space Flight

699

Bleeding and Ischemic Risks of Ticagrelor Monotherapy after Coronary Interventions

700

Right Atrial Adaptation to Precapillary Pulmonary Hypertension: Pressure-Volume, Cardiomyocyte and Histological Analysis

701

Risk of Arrhythmic Death in Patients with Non-Ischemic Cardiomyopathy: JACC Review Topic of the Week

702

ACC/AHA and ESC/EACTS Guidelines for the Management of Valvular Heart Diseases. JACC Guideline Comparison

703

JACC - August 15, 2023 Issue Summary

704

First-in-Human Transapical Beating-Heart Septal Myectomy in Patients with Hypertrophic Obstructive Cardiomyopathy

705

Subcutaneous Implantable Cardioverter Defibrillators in Patients with Congenital Heart Disease

706

Fatal Cardiac Arrhythmias During Electronic Gaming In Patients With Genetically Mediated Heart Diseases

707

Pulmonary Artery Hypoplasia in Neonates with Tetralogy of Fallot

708

Low Dose Colchicine (0.5 mg daily) for the Secondary Prevention of Coronary Artery Disease

709

Transformative Impact of Geroscience On Understanding Cvd In Older Adults And Developing New Therapeutic Strategies

710

JACC - August 8, 2023 Issue Summary

711

High-Sensitivity Cardiac Troponin for Risk Assessment in Patients with Chronic Coronary Artery Disease

712

Right Ventricular Function and Coupling to Pulmonary Circulation in Heart Failure with Preserved Ejection Fraction

713

Prognostic Performance of Right Ventricular Global Longitudinal Strain Measurements in Patients with Ebstein Anomaly

714

GLP1 Receptor Agonist Therapy with and without SGLT2 inhibitors in Patients with Type 2 Diabetes

715

Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Review Topic of the Week

716

Management of Worsening Heart Failure With Reduced Ejection Fraction: Jacc Review Topic of the Week

717

Bridging Treatment Implementation Gaps In Patients With Heart Failure: Jacc Focus Seminar

718

JACC - August 1, 2023 Issue Summary

719

Post-approval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System

720

Combination lipid-lowering therapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability

721

C-Reactive Protein and Risk of Incident Heart Failure in Patients with Cardiovascular Disease

722

Global Comparison of Re-admission Rates for Patients with Heart Failure

723

Mechanisms of Aortic Dilation in Patients with Bicuspid Aortic Valve: JACC: State-of-the-Art Review

724

JACC - July 25, 2023 Issue Summary

725

Short-term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice

726

Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial

727

Role of Human Epicardial Adipose Tissue-Derived miR-92a-3p in Myocardial Redox State

728

Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation